The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose
Abstract
No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1996Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose Peter J. Effert, Roland Bares, Stefan Handt, Johannes M. Wolff, Udalrich Bull, and Gerhard Jakse Peter J. EffertPeter J. Effert , Roland BaresRoland Bares , Stefan HandtStefan Handt , Johannes M. WolffJohannes M. Wolff , Udalrich BullUdalrich Bull , and Gerhard JakseGerhard Jakse View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66366-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated positron emission tomography (PET) with18 fluorine (sup 18 F)-labeled deoxyglucose for metabolic grading of untreated primary prostate cancer, and differentiation of benign and malignant prostatic disease. Materials and Methods: A total of 48 patients with untreated prostate cancer of different stages and 16 with histologically confirmed benign prostatic hyperplasia (BPH) underwent static PET after intravenous injection of 150 to 300 MBq.18 F-deoxyglucose. 18F-deoxyglucose accumulation was quantitated by calculating differential uptake ratios and prostate-to-skeletal muscle ratios. Results: Low18 F-deoxyglucose uptake was noted in the majority of primary tumors (81 percent).18 F-deoxyglucose accumulation did not correlate with increasing tumor grade or stage. There was a significant overlap in uptake values in BPH and malignant prostatic disease. A trend towards statistical significance was noted with lower prostate-to-skeletal muscle ratios in patients with BPH (p less than 0.07). Increased18 F-deoxyglucose accumulation was detected in some patients with BPH and malignant prostatic disease, as well as in those with lymph node and bone metastases of prostate cancer. Conclusions: 18 F-deoxyglucose PET does not allow for metabolic labeling in the majority of untreated primary prostate cancers. BPH and primary prostate cancer cannot be reliably differentiated on the basis of PET. Increased18 F-deoxyglucose accumulation occurs in some primary prostate tumors and in metastatic deposits of prostate cancer. References 1 : Cancer in the European Community and its member states. Eur. J. Cancer1990; 26: 1167. Google Scholar 2 Cancer Facts & Figures-1992. Atlanta: American Cancer Society1992. Google Scholar 3 : Stage D1 adenocarcinoma of the prostate. Urology1984; 23: 118. Google Scholar 4 : Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol.1988; 139: 1235. Link, Google Scholar 5 : Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. New Engl. J. Med.1990; 323: 621. Google Scholar 6 : The metabolism of tumors. London: Constable1930. Google Scholar 7 : Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J. Nucl. Med.1987; 28: 1123. Google Scholar 8 : Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and possibility of recurrence: a PET study. Radiology1987; 164: 521. Google Scholar 9 : Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR1988; 150: 189. Google Scholar 10 : PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J. Neurosurg.1988; 69: 830. Google Scholar 11 : The applications of PET in clinical oncology. J. Nucl. Med.1991; 32: 623. Google Scholar 12 : Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med.1993; 34: 12. Google Scholar 13 : Positron-emission-tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) in prostatic cancer (PC): first results. J. Nucl. Med.1993; 34: 217P. abstract 1021. Google Scholar 14 : Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imaging1982; 2: 113. Google Scholar 15 : Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J. Urol.1992; 148: 1457. Link, Google Scholar 16 : DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. J. Neurosurg.1989; 70: 86. Google Scholar 17 : Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer1988; 61: 1776. Google Scholar 18 : F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology1994; 192: 79. Google Scholar 19 : SPECT anti-CEA immunoscintigraphy (IS) and sup 18 F-FDG PET in the evaluation of colorectal carcinoma. Eur. J. Nucl. Med.1990; 16: 410. abstract 80. Google Scholar 20 : PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior to and after therap
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maximum Likelihood Reconstruction for Emission Tomography
Shepp, L. A., & Vardi, Y. (1982) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.1982.4307558 · Cited by 4,429
Bares, R., Klever, P., Hauptmann, S., Hellwig, D., Fass, J., Cremerius, U., Schumpelick, V, Mittermayer, C., & Büll, U. (1994) · Radiology · doi:10.1148/radiology.192.1.8208970 · Cited by 213
Self-citation
Cited by
Santos, C. R., & Schulze, A. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,335
Imaging Prostate Cancer: A Multidisciplinary Perspective
Hricak, H., Choyke, P. L., Eberhardt, S. C., Leibel, S. A., & Scardino, P. T. (2007) · Radiology · doi:10.1148/radiol.2431030580 · Cited by 601
Fatty acid oxidation: An emerging facet of metabolic transformation in cancer
Ma, Y., Temkin, S. M., Hawkridge, A. M., Guo, C., Wang, W., Wang, X.-Y., & Fang, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.006 · Cited by 531
Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids
Zaidi, N., Lupien, L., Kuemmerle, N. B., Kinlaw, W. B., Swinnen, J. V., & Smans, K. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.08.005 · Cited by 477
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Liu, Y. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500879 · Cited by 433
Metadata
- Authors
- Effert, P. J., Bares, R., Handt, S., Wolff, J. M., Bull, U., & Jakse, G.
- Venue
- Journal of Urology
- Published
- 1996-03
- Volume
- 155
- Issue
- 3
- Pages
- 994-998
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4365787468
- Cited by
- 240
- References
- 2
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose. https://app.cochat.ai/papers/10.1016/s0022-5347(01)66366-3
- The paper
- Effert, P. J., Bares, R., Handt, S., Wolff, J. M., Bull, U., & Jakse, G. (1996). Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)66366-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.